Secondary analysis of 40 Chinese patients in a phase 3 trial in cBTKi-pretreated CLL/SLL: IRC-assessed PFS favoured pirtobrutinib vs bendamustine/rituximab but was not significant (HR 0.281, 95% CI 0.070-1.125). Grade ≥3 AEs 36.8% vs 93.3%.
Secondary analysisn = 40
Yi et al. A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321